Navigation Links
Siteman Cancer Center at Barnes-Jewish and Washington University Begins Imaging with First ViewRay System
Date:7/11/2012

CLEVELAND, July 11, 2012 /PRNewswire/ -- Investigators at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri, have begun studying the imaging capabilities of an innovative radiation therapy system from ViewRay™ Incorporated. The ViewRay system is the first comprehensive image-guided radiation therapy system, providing a patented combination of simultaneous radiotherapy delivery and continuous magnetic resonance imaging (MRI) for the treatment of cancer. The Siteman Cancer Center is a national leader in the early adoption and use of advanced treatments for cancer patients.

The Siteman Cancer Center's clinical research began in January 2012, when imaging and simulated treatments were completed on the ViewRay system with a group of volunteer patients. Support for the research was partially provided by ViewRay. The purpose of the study was to assess the quality of images captured by ViewRay's MRI technology. The internal study involved 27 patients with various types of cancer, including lung, head and neck, breast, and prostate cancer. Most patients were scanned twice.

"It is important to evaluate any new technology early to assess potential clinical impacts," said Parag J. Parikh, MD, assistant professor of radiation oncology at the Siteman Cancer Center and lead investigator for the study. "We are comparing the new images with available radiation oncology imaging techniques and will report the results at upcoming scientific meetings."

High-quality soft-tissue imaging is an essential feature of the ViewRay system: MR images are used to plan treatments, position patients for treatment, and track each patient's position during treatment. "When physicians can clearly see the target, we are better able to adapt the treatment to changes in the patient's anatomy," said ViewRay Chief Medical Officer Prabhakar Tripuraneni, MD, FACR, FASTRO. "By verifying the high quality of the ViewRay system's images, the Siteman study establishes the potential value of MRI-guided radiation therapy."

ViewRay's integrated imaging and radiotherapy delivery system received marketing clearance from the U.S. FDA in May 2012.

About ViewRay
ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The ViewRay system provides continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. For more information, visit http://www.viewray.com.

About the Siteman Cancer Center
The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is the only National Cancer Institute Comprehensive Cancer Center in Missouri and within a 240-mile radius of St. Louis. Siteman is also one of only 20 national members of the National Comprehensive Cancer Network, an alliance of the world's leading cancer centers dedicated to improving the quality, effectiveness and efficiency of oncology practice so patients can live better lives. For more information, visit http://www.siteman.wustl.edu/.

ViewRay is a trademark of ViewRay Incorporated.

ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.

 

 


'/>"/>
SOURCE ViewRay Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BSGI Molecular Breast Imaging Proves Equivalent to MRI in Breast Cancer Patient Management
2. BSGI Molecular Breast Imaging Provides Better Results than MRI for Cancer Patients with Dense Breasts
3. Relief from Menopause Symptoms Short-lived for Prempro Women Suffering from Cancers
4. Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
5. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
6. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
7. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
8. Global Kidney Cancer Drugs Industry
9. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
10. Prostate Cancer Center of New Jersey the Latest Center to Achieve High Honor of ACR-ASTRO Accreditation
11. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:6/2/2017)...  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company ... demonstrating positive biochemical outcomes related to more frequent hemodialysis ... will be presented at the ERA-EDTA Congress being held ... . The research was conducted by ... Europe (KIHDNEy) Cohort team ...
(Date:5/30/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health ... it will be presenting at the 7th annual LD Micro Invitational ... Raphael , CEO, of DarioHealth will be giving the presentation and ... June 6th & 7th, 2017 at the Luxe Sunset Bel Air ... space. About LD Micro LD ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that puts them at ... Adam and Hal Kimowitz are currently accepting new patients at their practice for these ... for some patients, which is why they offer the latest in modern dental techniques ...
(Date:6/20/2017)... Linda, Ca (PRWEB) , ... June 20, 2017 ... ... of alternative polyA sites. To understand their regulatory principles, the research team developed ... mRNA-Seq, iCLIP and RNA motif analyses. This reveals at nucleotide resolution the ‘RNA ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... industry has been selected as the partner of choice by Amtrak to fulfill ... service that provides medium- and long-distance intercity service in the contiguous United States. ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniworld Boutique River ... aboard the line’s latest all-inclusive boutique ship, S.S. Joie de Vivre . What ... specifically for cruising France’s Seine River and designed small enough to dock directly in ...
(Date:6/20/2017)... , ... June 20, 2017 , ... The law firm ... on his installation as the president of the DuPage County Bar Association’s Board of ... Installation Dinner June 9 at the Drake in Oak Brook. Momkus McCluskey Roberts LLC ...
Breaking Medicine News(10 mins):